BPC-157 5mg

BPC 157 for sale

BPC 157 peptide, also known as Pentadecapeptide BPC 157, or Body Protection Compound 157, originated from a protein found in the human digestive system, has been shown in various studies to help with healing joint, tendon, muscle tissue, as well as nerve tissue.

What You Need to Know About BPC 157 Peptide

It is common knowledge that as people age, their body functioning abilities begin to decline. Usual functions such as wound healing tend to take longer processing times. With the increasing age, multiple changes occur in the body, such as gastrointestinal (GI) changes. These changes are mostly physiological and pathological, which usually leads to GI disorders in older people.

While there are many medications available to provide temporary relief, studies are still ongoing to discover more effective drugs with limited side effects. So far, peptides have been a promising candidate showing excellent efficient results.

One such peptide is BPC 157 which has proven results in wound healing, bowel disorders, damaged joints, and other health benefits.

Introduction

BPC 157 is a peptide composed of 15 amino acids with hepatoprotective benefits. As the name suggests, body protection compound (BPC) is an amino acid fragment isolated from the human body, particularly the gastric juice. (1)

BPC 157 is also commonly known as pentadecapeptide because of the 15 amino acids it is comprised of. Since these peptides are derived from human body, they are highly biocompatible and stable in humans, which has a great added advantage over other synthetic peptides. (1)

BPC 157 Backstory

The history of BPC 157 goes back to the 1890s during the initial discovery of the brain to gut axis.
It was in 1895 when a study was conducted sham-feeding the dogs with gastric fistula and the role of vagus nerve in controlling the secretion of gastric acid was understood (2). After several extensive studies carried out over the period of time to understand human anatomy and medical discoveries, the prominent effects of peptides to modify gastrointestinal secretions and reduce lesions was discovered during the mid-1980s. These effects were observed when administered within the hypothalamic site or cerebrospinal fluid (CSF), which led to peptides being a promising candidate in CNS and GI disorders (3).

Mechanism of action

How BPC 157 works in Wound Healing

Administration of BPC 157 stimulates the growth hormone (GH) receptors thereby inducing similar GH properties. BPC 157 peptide binds with the growth hormone receptors and stimulates cell proliferation. This leads to the development of the new tissue that is composed of collagen and developing a network of blood vessels, a process also called ‘angiogenesis.’ Consequently, the wound is ‘rebuilt’ and healed faster than the usual rate. (1)

How BPC 157 works in Maintaining Gut Health

Serotonin, an enteric neurotransmitter, is localized in the human GI tract and GI mucosa. Altered levels of serotonin may inhibit gastric acid secretion, thereby affecting gut mucosal function and influence gastric blood flow. (4)

BPC 157 has a particular antidepressant activity, which counteracts with the serotonin induced symptoms. The peptide counteracts with the 5-HT2A receptors; hence not allowing the serotonin to bind with these receptors and thereby inhibiting its effects. (3)

BPC 157 Benefits and Uses

Below are the main advantages of the peptide:

• Elevated wound healing effects
• Decline in pain levels
• Improved digestive functions
• Improved gut health and heals inflamed intestines
• Helps with Inflammatory Bowel Syndrome (IBS)
• Induces tendon, ligament, muscle, and bone healing

Multiple studies have since been conducted to understand the full potency of the peptide, especially in the area of healing gastrointestinal ulceration, which are further described in this article.

Studies conducted have shown the peptide to increase the build up of the blood vessels and induce anti-inflammation effects via improving the functional recovery. As a result, BPC 157 has great efficacy in the tendon, ligament, and bone healing processes. (5)

Peptide Research and Clinical Studies

BPC 157 Effects on Healing

In this study, three experimental models of rats were used – first with skin wounds, second with colon anastomosis and third with synthetic sponge implantation. Some of the rats were treated with placebo, whereas others were treated with BPC 157 peptide.

After the treatment, all models were histologically examined. It was discovered that the BPC 157 treated rats showed significantly higher numbers of collagen, reticulin and blood vessel development as compared to the ones treated with the control. This proved that the peptide promoted healing at a faster rate than usual, via formation of granulation tissue and angiogenesis.

What made this study more interesting was that not only did the peptide show therapeutic effects in different wounds, but it showed the same levels of efficacy even though it was administered via different routes – including intragastric and local administration – hence making BPC 157 peptide a potential therapeutic agent. (6)

BPC 157 for Tendon Healing

This experiment was conducted ex-vivo in the cultured tendon fibroblasts derived from the tendons of rat Achilles.

The cultures were divided into two groups, one was treated with control whereas the other was treated with BPC 157. Post treatment, the following was discovered (1):

• BPC 157 peptide significantly promoted the outgrowth of tendon and tendon healing.
• Even under H2O2 stress, BPC 157 cell survival under stress.
• With increased dosing, the peptide promoted migration of the tendon fibroblasts.
• High doses of BPC 157 induced increased levels of phosphorylation of both PAK and paxillin, while the total protein level remained unchanged in the body.

Upon analysis, it was discovered that the peptide promotes tendon healing, tendon outgrowth and cell survival via the F-actin formation and activation of the FAK and paxillin pathway. (1)

BPC 157 for Gastrointestinal Healing

This study was conducted to scrutinize the effects of BPC 157 peptide against similar angiogenic growth factors such as EGF, FGF and VEGF. The primary reason was the fact that BPC 157 is highly stable and biocompatible, and that BPC 157 can be administered all by itself.

While both showed improved healing, it was only BPC 157 that showed consistent results in all wound types (i.e., both chronic and acute) on the esophagus, stomach, duodenum, and lower GI tract. These effects were shown regardless of the route of administration, i.e. whether administered intraperitoneally, orally, or locally.

Thus, this study exhibited the extent of the angiogenic effects of the peptide – which was not only on local wounds and ligaments, but also on GI wounds and bone healing. (7)

Other Pharmacological Effects

This study was conducted to understand the extent of the angiogenic effects of the peptide, beyond local wounds, ligaments, and GI tract wounds; and to study its effect on multiple gastrointestinal lesions on the pancreas, liver injuries, heart damage, endothelium damage and blood pressure.

What was understood from this study is that BPC 157 induces a network of activities via peptidergic defense systems.

There are several important neurotransmitters and functions in our body such as dopamine, nitrous oxide, prostaglandin, and other neuron systems. Any over activity or inhibition of these systems may lead to several lesions in different organs of the body. BPC 157, through its defense system, counteracts with these systems and reverses their over activation and inhibition.

While further investigation in detail was yet pending, these initial studies demonstrated that BPC 157 is a ‘universal’ peptide that can be used due to the physiologic defense system it creates. (8)

BPC 157 for Muscle Healing

This study was conducted on rats with injured gastrocnemius muscle complex. These rats were then treated with methylprednisolone (corticosteroid). These corticosteroid rats were then divided into two groups: one group was treated with BPC 157, whereas the other was treated with placebo. Both medications were given intraperitoneally or locally, once in 24 hours and examined at days 1, 2, 4, 7, and 14.

Upon examination, it was noticed that the corticosteroid significantly worsened the muscle damage in the rats. However, those treated with BPC 157 showed signs of healing and complete restoration of the damaged gastrocnemius muscle along with its full functioning ability.

This result demonstrated that the peptide was able to reverse the effects of systemic corticosteroid treatment and was able to promote faster muscle healing. (9)

Effects in Amphetamine Induced Hypersensitivity

It has become a known fact during this study that BPC 157 has the ability to heal multiple different lesions – in GI tract, liver, pancreas, and others. This suggested that the peptide had some interaction with the dopamine system.

To investigate further, peptide BPC 157 was administered in the amphetamine (dopamine agonist) treated rats. BPC 157 was either given in prophylactic doses (10 micrograms / kg) or in therapeutic doses (10 ng/kg) – both via the intraperitoneal route of administration. It was observed that BPC 157 was able to completely reverse the amphetamine induced excitability in the rats.

Furthermore, rats were treated with another dopamine agonist, haloperidol (5 mg/kg) and then treated with amphetamine (10mg/kg) on days 1, 2, 4 and 10. These rats were then administered with BPC 157 to understand its effects. Upon examination, it was noted that the peptide caused an almost complete reversal of the haloperidol effect.

Thus, these studies provided strong evidence proving the interaction of BPC 157 with the dopamine system.(10)

BPC 157 Side Effects

BPC 157 so far has not demonstrated any serious side effects during any research studies.

Below are the common side effects as seen with most of the peptides:

• Pain, redness, and inflammation at the site of injection (most common)
• Itchiness
• Headache
• Dizziness, flushing
• Nausea
• Lethargy and drowsiness
• Changes in bowel habits
• Changes in hunger pattern

Depending on the individual profile (such as allergies, simultaneous consumption of other medicines, patient age and medical history), the side effects may vary amongst people. It is always highly recommended to consult a healthcare professional immediately upon prolonged adverse reactions after use.

BPC 157 Dosage, and Mode of Administration

Multiple research and clinical studies have been conducted for BPC 157 peptide with doses between 1 to 10 mcg per kg body weight (10) which would typically range from 200mcg to 800mcg daily.

While research is still ongoing, based on several research studies described above, BPC 157 has proven to be highly efficacious regardless of the route of administration. Successful studies have shown BPC 157 to be usually administered intraperitoneally, subcutaneously, orally and locally on skin. (7)(9)

While no preset time has been confirmed to show better BPC 157 results, it is recommended to administer the peptide at the same time every day, to maintain consistency and for better, effective results.

Is BPC157 clinically tested in humans?

BPC 157 has been tested in humans under study PL 14736 in early 2000s.

In order to comply with the regulatory requirements, a seven-day trial run was first carried out in rats where BPC 157 was administered via intracolonic route of administration. Once it was evident that the peptide did not induce any colonic damage, the clinical trial was approved.

In the first clinical trial in men, 32 healthy male volunteers were treated with BPC 157 enemas (rectal route of administration). Upon completion of the trial, physical examination, lab test results and clinical monitoring demonstrated that the peptide is highly tolerable, and no side effects were shown.

Based on this, it was determined that the following double blind, randomized study will be conducted on patients with ulcerative colitis, using BPC 157 enemas. Unfortunately, the details on the following study and consecutive results are sparse and not overly informative. (11)(12)

Later, in 2015, a randomized clinical trial was planned to be conducted on 42 healthy volunteers where BPC 157 would be administered orally in tablet form in doses of 0.25, 0.5, 1 and 2 micro / kg body weight. The result of this study remains pending. (11)(13)

Summary

True to its name, BPC 157 peptide or pentadecapeptide is a peptide composed of 15 amino acids (hence the name pentadecapeptide) and is isolated from human gastric juice. Since it is an isolated fragment from the human body, it is highly biocompatible and stable in the human body.

Multiple clinical studies have shown that BPC 157 is highly effective in multiple wound healing, regardless of the severity of the wound (i.e., can heal both acute and chronic wounds), effective results in ligament healing and wound repair in skin, muscles, gastrointestinal organs, pancreas, and others. Surprisingly, the peptide has yet shown no severe side effects after administration.

While there have been many studies carried out on rodents and primates, there is extremely limited information available on human trials pertaining to this peptide. From the current available literature, BPC 157 sure has a strong potential to be developed into novel therapy to aid in injuries in humans, although further research is required to understand its mechanism and efficacy in the human body.

References:

1. Chang, Chung-Hsun et al. “The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration.” Journal of applied physiology (Bethesda, Md. : 1985) vol. 110,3 (2011): 774-80. doi:10.1152/japplphysiol.00945.2010. https://pubmed.ncbi.nlm.nih.gov/21030672/

2. J.I. Farrell. Contributions to The Physiology of Gastric Secretion. 01 Jul 1928. https://doi.org/10.1152/ajplegacy.1928.85.3.685

3. Sikiric, Predrag et al. “Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications.” Current neuropharmacology vol. 14,8 (2016): 857-865. doi:10.2174/1570159x13666160502153022. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5333585/#r1

4. Ormsbee, H S 3rd, and J D Fondacaro. “Action of serotonin on the gastrointestinal tract.” Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.) vol. 178,3 (1985): 333-8. doi:10.3181/00379727-178-42016. https://pubmed.ncbi.nlm.nih.gov/3919396/

5. Krivic, A., Majerovic, M., Jelic, I. et al. Modulation of early functional recovery of Achilles tendon to bone unit after transection by BPC 157 and methylprednisolone. Inflamm. res. 57, 205–210 (2008). https://doi.org/10.1007/s00011-007-7056-8

6. S Seiwerth, et al. “BPC 157's effect on healing.” Journal of physiology, Paris vol. 91,3-5 (1997): 173-8. doi:10.1016/s0928-4257(97)89480-6. https://pubmed.ncbi.nlm.nih.gov/9403790/

7. Seiwerth, Sven et al. “BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing.” Current pharmaceutical design vol. 24,18 (2018): 1972-1989. doi:10.2174/1381612824666180712110447. https://pubmed.ncbi.nlm.nih.gov/29998800/

8. “The pharmacological properties of the novel peptide BPC 157 (PL-10).” Inflammo-pharmacology vol. 7,1 (1999): 1-14. doi:10.1007/s10787-999-0022-z. https://pubmed.ncbi.nlm.nih.gov/17657443/

9. Pevec D, Novinscak T, Brcic L, Sipos K, Jukic I, Staresinic M, Mise S, Brcic I, Kolenc D, Klicek R, Banic T, Sever M, Kocijan A, Berkopic L, Radic B, Buljat G, Anic T, Zoricic I, Bojanic I, Seiwerth S, Sikiric P. Impact of pentadecapeptide BPC 157 on muscle healing impaired by systemic corticosteroid application. Med Sci Monit. 2010 Mar;16(3):BR81-88. PMID: 20190676. https://pubmed.ncbi.nlm.nih.gov/20190676/

10. Jelovac, N et al. “A novel pentadecapeptide, BPC 157, blocks the stereotypy produced acutely by amphetamine and the development of haloperidol-induced supersensitivity to amphetamine.” Biological psychiatry vol. 43,7 (1998): 511-9. doi:10.1016/s0006-3223(97)00277-1. https://pubmed.ncbi.nlm.nih.gov/9547930/

11. Gwyer, D., Wragg, N.M. & Wilson, S.L. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res 377, 153–159 (2019). https://doi.org/10.1007/s00441-019-03016-8

12. Veljaca, Marija et al, The development of PL 14736 for treatment of inflammatory bowel disease, Advanced in GI pharmacology, 2002 O-32. https://www.bib.irb.hr/192824

13. Phase I clinical trial in healthy volunteers to study safety and pharmacokinetics of BPC-157, a pentadecapeptide from gastric source. https://clinicaltrials.gov/ct2/show/NCT02637284?

Latest Post

Find out more details about this remarkable peptide by reading our latest BPC 157 Review - Benefits, Side Effects 2021 blog post.

NOTE: These products are intended for laboratory research use only. BPC 157 for sale is not for personal use. Please review and adhere to our Terms and Conditions before ordering.